Zenas BioPharma (ZBIO) Stock Price, News & Analysis

Company Overview

Zenas BioPharma, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies. Its integrated research infrastructure encompasses medicinal chemistry, in vitro and in vivo pharmacology, as well as manufacturing capabilities to support rapid progression of lead molecules into clinical development.

The company’s pipeline includes immuno-oncology candidates designed to modulate checkpoint pathways in solid tumors, alongside antiviral programs targeting broad-spectrum viral threats. Each program is engineered to combine high specificity with favorable pharmacokinetic properties, with key assets currently in IND-enabling stages and early clinical trials.

To advance its programs, Zenas BioPharma collaborates with academic institutions and contract research organizations, leveraging external expertise and resources. Serving global markets, the company is committed to addressing unmet medical needs and bringing differentiated therapies to patients worldwide.

Key Stats

• Today's Range: $29.50 to $31.18
• 50-Day Range: $17.76 to $32.82
• 52-Week Range: $13.50 to $44.60
• Volume: 543,656 shs
• Average Volume: 844,069 shs
• Market Capitalization: $1.99 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $45.71
• Consensus Rating: Moderate Buy

Zenas BioPharma Stock Analysis - MarketRank™

Zenas BioPharma scored higher than 53% of companies evaluated by MarketBeat, and ranked 513th out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Zenas BioPharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Zenas BioPharma has a consensus price target of $45.71, representing about 51.9% upside from its current price of $30.10.

Amount of Analyst Coverage

Zenas BioPharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Zenas BioPharma are expected to grow in the coming year, from ($5.81) to ($4.87) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Zenas BioPharma is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zenas BioPharma is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Zenas BioPharma has a P/B Ratio of 7.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

23.87% of the float of Zenas BioPharma has been sold short.

Short Interest Ratio / Days to Cover

Zenas BioPharma has a short interest ratio ("days to cover") of 13.83, which indicates bearish sentiment.

Change versus previous month

Short interest in Zenas BioPharma has recently decreased by 3.42%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Zenas BioPharma does not currently pay a dividend.

Dividend Growth

Zenas BioPharma does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: -0.02

News Sentiment

Zenas BioPharma has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 18 news articles for Zenas BioPharma this week, compared to 5 articles on an average week.

Search Interest

5 people have searched for ZBIO on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.

MarketBeat Follows

3 people have added Zenas BioPharma to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Zenas BioPharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

22.00% of the stock of Zenas BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Zenas BioPharma has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 8/20/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ZBIO
• Previous Symbol: NASDAQ:ZBIO
• CIK: 1953926
• Web: zenasbio.com
• Phone: (857) 271-2954
• Fax: N/A
• Employees: N/A
• Year Founded: 2019

Price Target and Rating

• Average Price Target for Zenas BioPharma: $45.71
• High Price Target: $55.00
• Low Price Target: $32.00
• Potential Upside/Downside: +48.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.56
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($8.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$377.74 million
• Net Margins: N/A
• Pretax Margin: -48,416.40%
• Return on Equity: -122.45%
• Return on Assets: -58.04%

Debt

• Debt-to-Equity Ratio: 1.57
• Current Ratio: 9.93
• Quick Ratio: 9.93

Sales & Book Value

• Annual Sales: $10 million
• Price / Sales: 200.36
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.79 per share
• Price / Book: 8.11

Miscellaneous

• Outstanding Shares: 65,180,000
• Free Float: 50,838,000
• Market Cap: $2.00 billion
• Optionable: N/A
• Beta: -1.03